JAMA Oncology Study Confirms Oncotype DX Test Effectiveness Across All Racial and Ethnic Groups
• Comprehensive JAMA Oncology review validates that the Oncotype DX Breast Recurrence Score test accurately predicts chemotherapy benefit for breast cancer patients regardless of race or ethnicity.
• The largest real-world SEER registry analysis to date, involving over 171,000 breast cancer patients, provides new evidence supporting the test's consistent performance across diverse populations.
• Despite a 40% higher breast cancer mortality rate among non-Hispanic Black women compared to non-Hispanic White women, the study confirms the test's reliability in guiding precision treatment decisions for all patients.
Exicure Secures Australian Patent for Novel Cancer Treatment Targeting CXCR4 and GPCRx
• Exicure (NASDAQ: XCUR) has been granted Australian Patent No. 2018388302 for its innovative combination approach targeting CXCR4 and GPCRx in cancer treatment.
• The patent supports Exicure's ongoing Phase 2 clinical trial evaluating GPC-100 and propranolol combination in multiple myeloma patients, aiming to enhance hematopoietic stem cell mobilization.
• This intellectual property has already been secured in the United States, Japan, and Taiwan, strengthening Exicure's global patent portfolio for its proprietary co-targeting approach.
Exicure Acquires GPCR USA to Advance Clinical-Stage Biotech Pipeline
• Exicure, Inc. signed an MOU with GPCR Therapeutics to acquire GPCR USA, securing key personnel and clinical pipelines.
• The acquisition includes technology transfer for GPCR's CXCR4 inhibitor, currently in Phase 2 trials for multiple myeloma, with a $1-2 billion market.
• Exicure plans collaborative R&D with GPCR Therapeutics in immuno-oncology, fibrosis, and obesity, expanding its therapeutic focus.
• With recent capital investments totaling $14 million, Exicure aims to advance as a clinical-stage biotech company.
© Copyright 2025. All Rights Reserved by MedPath